The PI3K/AKT/mTOR signaling pathway is among the most frequently altered pathways in human cancer, and mutations in the AKT kinase family represent a compelling therapeutic target across multiple tumor types. Ongoing research into clinical trials for AKT1/2/3 mutant-positive tumors is rapidly expanding treatment options for patients whose cancers carry these specific genetic alterations.
Key Takeaways
- AKT1, AKT2, and AKT3 are serine/threonine kinases whose activating mutations drive uncontrolled tumor growth across multiple cancer types.
- Multiple clinical trials are currently enrolling patients with AKT-mutant solid tumors, with several pan-AKT inhibitors demonstrating meaningful clinical activity.
- Capivasertib received FDA approval in combination with fulvestrant for certain AKT-mutant breast cancers, validating AKT as a druggable target.
- Molecular tumor testing is a prerequisite for enrollment in most AKT mutation–targeted trials.
- Eligibility criteria typically require documented AKT pathway alterations confirmed by next-generation sequencing or comparable genomic profiling.
Understanding AKT1, AKT2, and AKT3 Mutations in Cancer
AKT refers to a family of three closely related serine/threonine protein kinases—AKT1, AKT2, and AKT3—that function as central regulators of cell survival, proliferation, and metabolism downstream of phosphoinositide 3-kinase (PI3K). When any of these kinases acquires an activating mutation, the result is constitutive signaling that overrides normal cellular checkpoints, promoting tumor growth and resistance to standard therapies. Collectively, alterations across the AKT isoforms occur in a broad range of solid tumors, making them among the most actionable oncology targets identified in the genomic era.
The most well-characterized alteration is the AKT1 E17K point mutation, identified in breast, colorectal, bladder, and endometrial cancers, among others. AKT2 amplification is frequently observed in ovarian and pancreatic malignancies, while AKT3 overexpression has been linked to melanoma and certain brain tumors. According to data aggregated in large genomic databases such as cBioPortal, AKT pathway alterations—including mutations, amplifications, and fusions—appear in approximately 3–5% of all solid tumor samples profiled, with frequencies rising to 8–10% in select histologies such as hormone receptor–positive breast cancer and endometrial carcinoma.
The oncogenic impact of these mutations extends beyond simple kinase activation. Mutant AKT isoforms can interact differently with downstream effectors such as mTORC1, GSK-3β, and FOXO transcription factors, contributing to unique dependencies that vary by isoform and tumor context. This biological heterogeneity is one reason why broad, isoform-agnostic inhibition strategies have gained traction in clinical development, and why comprehensive genomic profiling is now standard practice before enrolling patients in AKT mutation cancer clinical trials.
Active Clinical Trials for AKT1/2/3 Mutant-Positive Tumors
The clinical trial landscape targeting AKT-mutant cancers has expanded considerably over the past several years. The landmark CAPItello-291 trial demonstrated that capivasertib combined with fulvestrant significantly improved progression-free survival in patients with AKT1/2/3-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, leading to FDA approval in November 2023. This regulatory milestone validated the AKT pathway as a clinically meaningful target and accelerated broader investment in related studies. Researchers conducting AKT inhibitor trials for mutant-positive solid tumors are now testing pan-AKT agents across a much wider range of histologies.
Beyond breast cancer, investigators are actively enrolling patients in studies that examine AKT inhibition in endometrial, ovarian, prostate, non-small cell lung, and colorectal cancers harboring pathway-activating alterations. Several Phase I/II basket trials—designed to enroll patients based on molecular profile rather than tumor histology—are currently listed on ClinicalTrials.gov and accept participants with documented AKT1, AKT2, or AKT3 mutations regardless of primary tumor site. These tumor-agnostic designs reflect a broader shift in oncology toward biomarker-driven rather than organ-based trial enrollment.
Combination strategies represent another active frontier. Current AKT1/2/3 oncology mutation treatment studies are pairing AKT inhibitors with CDK4/6 inhibitors, PARP inhibitors, immune checkpoint blockade, and endocrine therapies to address resistance mechanisms and enhance efficacy. Early-phase data from several of these combinations have shown manageable safety profiles, supporting advancement into randomized cohorts. Patients and oncologists are encouraged to consult ClinicalTrials.gov regularly, as enrollment windows for these studies open and close frequently.
AKT Inhibitors Under Investigation in Mutant-Positive Solid Tumors
Several small-molecule AKT inhibitors are currently under clinical investigation, each with distinct pharmacological profiles. Capivasertib (AstraZeneca/Genentech) is the most advanced, having already secured regulatory approval in one indication. Ipatasertib (Genentech/Roche) is being evaluated in prostate and breast cancers across multiple ongoing studies, including Phase III trials examining its role in combination with taxane chemotherapy and androgen receptor–pathway agents. MK-2206, an allosteric AKT inhibitor, has been studied extensively in early-phase settings and continues to appear in combination regimens within academic trial portfolios.
The table below summarizes the principal AKT inhibitors currently under clinical evaluation and their primary development contexts.
| AKT Inhibitor | Mechanism | Primary Tumor Indications Under Study | Development Stage |
|---|---|---|---|
| Capivasertib | ATP-competitive, pan-AKT | Breast, endometrial, prostate | FDA-approved (breast); Phase II/III in others |
| Ipatasertib | ATP-competitive, pan-AKT | Prostate, breast, ovarian | Phase II/III |
| MK-2206 | Allosteric, pan-AKT | Multiple solid tumors (basket) | Phase I/II |
| Afuresertib | ATP-competitive, pan-AKT | Hematologic and solid tumors | Phase I/II |
Ongoing clinical studies targeting AKT-mutant cancers are also interrogating predictive biomarkers beyond the primary AKT mutation itself. Co-occurring alterations in PTEN loss, PIK3CA mutation, and RAS pathway activation may influence response and resistance, prompting researchers to collect comprehensive genomic data at baseline and at progression. This biomarker-rich approach is helping to define which patient subgroups derive the greatest benefit from AKT-directed therapy, a question that will ultimately shape how these agents are incorporated into standard care.
Tolerability has emerged as a key consideration in AKT kinase mutation tumor therapy clinical research. Hyperglycemia, rash, diarrhea, and fatigue are the most frequently reported adverse events associated with AKT inhibitors across trials. Intermittent dosing schedules—used in some capivasertib studies—have demonstrated improved tolerability without substantially compromising drug exposure, suggesting that schedule optimization may be as important as dose selection in future trial designs.
Eligibility and Enrollment in AKT Mutation Cancer Clinical Trials
Participation in AKT mutant-positive tumor targeted therapy trials typically begins with molecular tumor testing. Next-generation sequencing (NGS) of tumor tissue or circulating tumor DNA (ctDNA) is the standard method for detecting AKT1, AKT2, or AKT3 mutations, amplifications, or other actionable alterations. Many academic medical centers and commercial laboratories offer comprehensive genomic profiling panels that cover the entire AKT family alongside hundreds of other cancer-relevant genes. Patients who have not yet undergone molecular testing are strongly encouraged to discuss this option with their oncologist, as a confirmed AKT pathway alteration is a prerequisite for most targeted trials.
Beyond molecular eligibility, standard performance status requirements apply. Most Phase II and III trials require an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate organ function, and a defined number of prior lines of therapy. Some early-phase studies are more flexible with prior treatment history, particularly when evaluating novel combinations. Patients with certain comorbidities—uncontrolled diabetes, for example—may face additional screening scrutiny given the known hyperglycemic effect of AKT inhibitors.
How to Identify Relevant Trials
ClinicalTrials.gov remains the primary public registry for identifying open studies. Patients and caregivers can search using terms such as “AKT mutation,” “AKT inhibitor,” or specific tumor histologies combined with biomarker filters. Many academic cancer centers also maintain dedicated molecular tumor boards or precision oncology programs that can match patients to appropriate studies based on their genomic report. Patient advocacy organizations focused on specific cancer types frequently maintain trial-matching resources and can facilitate introductions to principal investigators.
Informed Consent and Ongoing Participation
Enrollment in any clinical trial requires informed consent, during which the study team explains potential benefits, risks, time commitments, and alternatives. Participants in AKT-targeted trials should expect regular blood draws, periodic imaging assessments, and pharmacokinetic sampling in earlier-phase studies. Many trials also collect serial tumor biopsies to evaluate on-treatment biomarker dynamics. Patients retain the right to withdraw at any time, and trial participation does not preclude access to standard-of-care therapies unless specifically noted in the protocol.
Frequently Asked Questions
Who is eligible to enroll in clinical trials targeting AKT-mutant tumors?
Eligibility generally requires a confirmed AKT1, AKT2, or AKT3 mutation or pathway alteration identified through validated genomic testing. Additional criteria typically include adequate organ function, an acceptable performance status (usually ECOG 0–1), and a defined prior treatment history. Some basket trials accept patients with any advanced solid tumor harboring an AKT alteration, regardless of histology. Patients should review specific inclusion and exclusion criteria on ClinicalTrials.gov or discuss eligibility directly with a trial site coordinator.
Are AKT inhibitors currently approved for any cancer type?
Yes. Capivasertib received FDA approval in November 2023 for use in combination with fulvestrant in adults with AKT1/2/3-mutant, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer following progression on at least one prior endocrine-based regimen. This approval was based on data from the CAPItello-291 Phase III trial. Other AKT inhibitors, including ipatasertib, remain investigational outside of ongoing studies.
How does molecular testing factor into AKT mutation trial enrollment?
Molecular testing is a foundational step. Most AKT mutation–targeted clinical trials require documentation of an AKT1, AKT2, or AKT3 alteration from a validated NGS assay performed on tumor tissue or circulating tumor DNA. Results from CLIA-certified commercial platforms are generally accepted. Patients who lack prior molecular profiling may have the option to undergo testing through the trial sponsor or an affiliated laboratory. Accurate genomic characterization ensures patients are matched to therapies most likely to benefit their specific mutation profile.
